| P/E (FY) | — | Sales (TTM) | $839,000 |
| Earnings (TTM) | -$75.0M | ROE | −90.27% |
| Net Margin | −15851.88% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −70.45% |
| Market Cap | $1.64B | Trading Days | 1360 |
| 52W High | 12.19 |
| 52W Low | 4.19 |
| % Off High | −5.25% |
| YTD | 89.97% | 1Y | 95.10% |
| 3Y | 110.00% | 5Y | −55.58% |
| Since incept. (ann.) | −15.03% |
GB 100%
| Ann. Volatility (1Y) | 80.36% | Ann. Volatility (3Y) | 81.53% |
| Sharpe (1Y) | 1.24 | Sharpe (3Y) | 0.72 |
| Max Drawdown (1Y) | −41.89% | Max Drawdown (3Y) | −91.70% |
| Beta (3Y, vs SPY) | 2.40 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | $1.63B | — |
| ZYME | Zymeworks Inc. | $1.65B | — |
| ABCL | AbCellera Biologics Inc. | $1.62B | — |
| INVA | Innoviva, Inc. | $1.61B | 6.6 |
| GENB | Generate Biomedicines, Inc. | $1.68B | — |
| BHC | Bausch Health Companies Inc. | $1.69B | 10.8 |
| SNDX | Syndax Pharmaceuticals Inc | $1.74B | — |
| SEPN | Septerna, Inc. | $1.53B | — |
| BCAX | Bicara Therapeutics Inc. | $1.77B | — |
| ANAB | ANAPTYSBIO, INC | $1.52B | — |
| XNCR | Xencor Inc | $1.48B | — |
| PAHC |
| PHIBRO ANIMAL HEALTH CORP |
| $1.48B |
| 30.6 |
